ArticleJournal of experimental & clinical cancer research : CR2011
miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level.
Article in Journal of experimental & clinical cancer research : CR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Lack of association between IL-4 -588C>T polymorphism and NHL susceptibility.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- MicroRNAs as Modulators of the Immune Response in T-Cell Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2022Review
- Leukemic Stem Cell: A Mini-Review on Clinical Perspectives.Frontiers in oncology · 2022Review
- MicroRNA-9 restrains the sharp increase and boost apoptosis of human acute myeloid leukemia cells by adjusting the Hippo/YAP signaling pathway.Bioengineered · 2021Article
- A review on interplay between small RNAs and oxidative stress in cancer progression.Molecular and cellular biochemistry · 2021Review
- MicroRNA as a Prognostic and Diagnostic Marker in T-Cell Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2021Review
- Physical Activity as a Preventive Lifestyle Intervention Acts Through Specific Exosomal miRNA Species-Evidence From Human Short- and Long-Term Pilot Studies.Frontiers in physiology · 2021Article
- Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.Journal of clinical laboratory analysis · 2020Article
- MicroRNAs Associated With a Good Prognosis of Acute Myeloid Leukemia and Their Effect on Macrophage Polarization.Frontiers in immunology · 2020Review
- A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy.Frontiers in oncology · 2020Review
- Conserved temporal ordering of promoter activation implicates common mechanisms governing the immediate early response across cell types and stimuli.Open biology · 2018Article
- Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment.Stem cells translational medicine · 2018Review
- EngineeredJournal of biological engineering · 2018Review
- Article
- Cytoplasmic Localization of WT1 and Decrease of miRNA-16-1 in Nephrotic Syndrome.BioMed research international · 2017Article
- Article
- [miR-202 contributes to sensitizing MM cells to drug significantly via activing JNK/SAPK signaling pathway].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers.Journal of experimental & clinical cancer research : CR · 2016Article
- MiR-16 regulates mouse peritoneal macrophage polarization and affects T-cell activation.Journal of cellular and molecular medicine · 2016Article
- Long non-coding RNA CCAT2 functions as an oncogene in hepatocellular carcinoma, regulating cellular proliferation, migration and apoptosis.Oncology letters · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundmiR-15a and miR-16-1(miR-15a/16-1) have been implicated as tumor suppressors in chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemic cells. However the mechanism of inhibiting the proliferation of leukemic cells is poorly understood.
methodsK562 and HL-60 cells were transfected with pRS-15/16 or pRS-E, cell growth were measured by CCK-8 assay and direct cell count. Meanwhile WT1 protein and mRNA level were measured by Western blotting and quantitative real-time PCR.
resultsIn this study we found that over-expression of miR-15a/16-1 significantly inhibited K562 and HL-60 cells proliferation. Enforced expression of miR-15a/16-1 in K562 and HL-60 cells significantly reduced the protein level of WT1 but not affected the mRNA level. However enforced expression of miR-15a/16-1 can not reduce the activity of a luciferase reporter carrying the 3'-untranslated region(3'UTR) of WT1. Silencing of WT1 by specific siRNA suppressed leukemic cells proliferation resembling that of miR-15a/16-1 over-expression. Anti-miR-15a/16-1 oligonucleotides (AMO) reversed the expression of WT1 in K562 and HL-60 cells. Finally, we found a significant inverse correlation between miR-15a or miR-16-1 expression and WT1 protein levels in primary acute myeloid leukemia (AML) blasts and normal controls.
conclusionsThese data suggest that miR-15a/16-1 may function as a tumor suppressor to regulate leukemic cell proliferation potentially by down-regulating the WT1 oncogene. However WT1 is not directly targeted by miR-15a/16-1 through miRNA-mRNA base pairing, therefore more study are required to understand the mechanism by which miR-15a/16-1 downregulate WT1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.